COMMUNIQUÉS West-GlobeNewswire

LIDDS presenterar bokslutskommuniké 2017
22/02/2018
BOKSLUTSKOMMUNIKÉ 2017 FJÄRDE KVARTALET - OKTOBER - DECEMBER 2017 Nettoomsättningen uppgick till 0,4 (0,0) KSEK Kostnaderna uppgick till 2,5 (2,1) MSEK Resultatet före och efter skatt uppgick till -2,2 (-2,1) MSEK [...]
Ossur Hf : Final agenda and proposals for the Annual General Meeting 8 March 2018
22/02/2018
Announcement no. 12/2018 Reykjavik, 22 February 2018 Final agenda and proposals Enclosed is the final agenda and proposals for Össur's Annual General Meeting, to be held on Thursday 8 March 2018. The meeting will be [...]
Financière de Tubize SA: Annual financial Report
22/02/2018
Press release 22 February 2018 - 8:00h CET FINANCIERE DE TUBIZE SA/NV Allée de la Recherche 60, 1070 Brussels Contact: Anne Sophie Pijcke, directeur, aspijcke@icloud.com Annual financial report 2017 Regulated [...]
Financière de Tubize SA: Rapport financier annuel
22/02/2018
Communiqué de presse 22 février 2018 - 8:00h CET FINANCIERE DE TUBIZE SA Allée de la Recherche 60, 1070 Bruxelles Contact: Anne Sophie Pijcke, directeur, aspijcke@icloud.com Rapport financier annuel 2017 Information [...]
William Demant Holding A/S: Annual Report 2017
22/02/2018
Company announcement no 2018-02 22 February 2018 Publication of Annual Report 2017 Organic growth of 9% in Group revenue, with strong performances by all business activities Hearing aid wholesale generated organic [...]
Treatment with Novartis' Ultibro® Breezhaler® improved cardiac function in COPD patients with lung hyperinflation
22/02/2018
Ultibro ® Breezhaler ® provided significant improvements in cardiac and lung function in COPD patients with lung hyperinflation, compared to placebo CLAIM is the first study to investigate the effect of dual [...]
NEOVACS STRENGTHENS ITS INTELLECTUAL PROPERTY IN THE USA
22/02/2018
PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS STRENGTHENS ITS INTELLECTUAL PROPERTY IN THE USA This patent covers IFNalpha Kinoid and its application in all diseases related to an overproduction of IFNalpha [...]
NÉOVACS RENFORCE SA PROPRIÉTÉ INTELLECTUELLE AUX ÉTATS-UNIS
22/02/2018
COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE NÉOVACS RENFORCE SA PROPRI É T É INTELLECTUELLE AUX ÉTATS-UNIS Ce brevet porte sur l'IFNalpha Kinoïde et son utilisation dans les maladies liées à la [...]
Santhera Completes Capital Increase to Settle Obtained License from Polyphor
22/02/2018
Pratteln, Switzerland, February 22, 2018 - Santhera Pharmaceuticals (SIX: SANN) announces that its share capital recorded in the commercial register was increased from 6,279,857 shares by 247,622 shares to 6,527,479 [...]
ABLYNX ANNOUNCES 2017 FULL YEAR RESULTS
22/02/2018
REGULATED INFORMATION A year of many momentous moments GHENT, Belgium, 22 February 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced its financial results for the year ended 31 st December 2017, which [...]
MDxHealth_FY_Results EN
22/02/2018
NEWS RELEASE REGULATED INFORMATION ANNUAL FINANCIAL REPORT MDxHealth Reports Financial Year 2017 Results Product revenue of $28 million up 13% and total revenue of $40 million up 35% with continued strong volume growth [...]
MDxHealth_FY_Results FR
22/02/2018
COMMUNIQUÉ DE PRESSE INFORMATION REGLEMENTÉE RAPPORT FINANCIER ANNUEL MDxHealth communique ses résultats financiers pour l'exercice 2017 Le chiffre d'affaires total est en hausse de 35 % et les revenus liés aux produits [...]
Biocartis Group NV: Biocartis to host webcast for announcement 2017 financial results on 1 March 2018
22/02/2018
PRESS RELEASE: REGULATED INFORMATION 22 February 2018, 07:00 CET BioCARTIS to Host Webcast FOR ANNOUNCEMENT 2017 FINANCIAL Results on 1 March 2018 Mechelen, Belgium, 22 February 2018 - Biocartis Group NV (the 'Company' [...]
argenx to host conference call & webcast to report fourth quarter business update and full year 2017 financial results on March 1, 2018
22/02/2018
February 22, 2018 Breda, the Netherlands / Ghent, Belgium argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the [...]
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
22/02/2018
COPENHAGEN, Denmark, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND ), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 3,947,368 [...]
Primary Endpoint Successfully Achieved in Mesoblast’s Phase 3 Cell Therapy Trial for Acute Graft Versus Host Disease
22/02/2018
NEW YORK and MELBOURNE, Australia, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO ) (ASX:MSB) today announced that the Phase 3 trial of its allogeneic mesenchymal stem cell product candidate MSC-100- [...]
Genesis Announces New Financing Commitments and Provides Updates to Previously Announced Restructuring Plans
21/02/2018
$70 Million of Additional Liquidity from New and Expanded Loan Commitments $54 Million of Annual Lease Reductions Effective January 1, 2018 KENNETT SQUARE, Pa., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Genesis HealthCare (NYSE [...]
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
21/02/2018
BRIDGEWATER, N.J., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced the granting of [...]
Loxo Oncology Announces Publication of Larotrectinib Clinical Data in The New England Journal of Medicine
21/02/2018
– Marked and Durable Responses Across TRK Fusion Cancers – – 75 Percent Overall Response Rate by Central Assessment; 80 Percent Overall Response Rate by Investigator Assessment – – 86 Percent of Responding Patients [...]

Pages